Generic Sweden (GENI) investor relations material

Executive summary

• Revenue grew 3.0% in Q4 2025 to 49.2 MSEK and 4.1% for the full year to 183.7 MSEK compared to the previous year.

• Gross profit increased 4.8% in Q4 and 12.3% for the year, with gross margin rising to 44.1% for 2025.

• EBIT decreased 11.0% in Q4 but rose 15.8% for the year, with EBIT margin at 21.0% for 2025.

• Cash flow from operations improved significantly both in Q4 and for the full year.

• Dividend proposal of 1.75 SEK per share, up from 1.60 SEK.

Financial highlights

• Q4 net income per share was 0.65 SEK (down from 0.74 SEK); full-year EPS was 2.52 SEK (up from 2.22 SEK).

• Cash and cash equivalents at year-end were 58.2 MSEK, up from 40.6 MSEK.

• Equity at year-end was 66.6 MSEK, up from 55.2 MSEK.

• No interest-bearing debt at year-end.

• Market capitalization at year-end was approximately 570 MSEK.

Outlook and guidance

• Continued focus on strengthening the organization and automation to drive efficiency.

• Anticipates further growth in messaging and DOCS product areas, with RCS introduction expected in 2026.

• Demand for secure communication solutions remains strong, especially in healthcare and public sectors.